Drugs / 14028
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05459285 | May → Jul 2022 | type 2 diabetes mellitus | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 14028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05459285 ↗ |
| Known as | HEC14028 | “This study aimed to evaluate the pharmacokinetics (PKs), safety, and immunogenicity of the biosimilar HEC14028 compared to reference Trulicity® (dulaglutide) in healthy male...” PMID 38651744 ↗ Apr 2024 |
| Route | Subcutaneous | “14028 injection, single dose, s.c. injection” NCT05459285 ↗ |